Bionter has raised its capital cover by a total of 3 million US dollars. The seed funding round for the Basel-based expert in testing sub-visible particles in liquid biologics was led by the venture capital company Dynamk Capital based in New York.
According to a press release, this funding accelerates the “already exceptional momentum” of Bionter’s first product. This comprehensive solution involves a particle counter with single-use consumables, maintenance, and training. It is suitable for use in the pharmaceuticals sector and is based on a new combination of light obscuration technology and smart automation.
Bionter’s device aims to minimize the number of costly samples used to determine the particle count, increase efficiency, and reduce human interaction. According to the information provided, this improves the reliability of measurements, data integrity, and thus patient safety. Development for this patented technology has been concluded. It is expected to come to market at the end of 2022.
Bionter CEO Dr. Tobias Werk states: “This financing enables us to bring our first product to our customers while driving the development of new innovations. We are thrilled to have Dynamk Capital join our team, as they provide a wealth of experience growing life science tools companies and help position Bionter and help us to make our vision a reality.”
